# Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

> **NCT02031445** · PHASE2 · TERMINATED · sponsor: **Celsus Therapeutics PLC** · enrollment: 73 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** MRX-6
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02031445
- **Lead sponsor:** Celsus Therapeutics PLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Interim analysis showed lack of efficacy
- **Last updated:** 2016-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02031445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02031445, "Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02031445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*